Related references
Note: Only part of the references are listed.The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2022)
Development of a First-in-Class Small-Molecule Inhibitor of the C-Terminal Hsp90 Dimerization
Sanil Bhatia et al.
ACS CENTRAL SCIENCE (2022)
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Dachuan Zeng et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Inflammation accelerates BCR-ABL1+ B-ALL development through upregulation of AID
Ping Zhang et al.
BLOOD ADVANCES (2022)
Selective Inhibition of the Hsp90α Isoform
Sanket J. Mishra et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Heat shock protein-90alpha (Hsp90α) stabilizes hypoxia-inducible factor-1α (HIF-1α) in support of spermatogenesis and tumorigenesis
Xin Tang et al.
CANCER GENE THERAPY (2021)
Heterogeneous Responses and Isoform Compensation Dim the Therapeutic Window of Hsp90 ATP-Binding Inhibitors in Cancer
Xin Tang et al.
MOLECULAR AND CELLULAR BIOLOGY (2021)
Heat Shock Protein 90 Triggers Multi-Drug Resistance of Ovarian Cancer via AKT/GSK3β/β-Catenin Signaling
Lan Yin et al.
FRONTIERS IN ONCOLOGY (2021)
HSP90 inhibitor NVP-BEP800 affects stability of SRC kinases and growth of T-cell and B-cell acute lymphoblastic leukemias
Rony Mshaik et al.
BLOOD CANCER JOURNAL (2021)
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
M. Nieves Calvo-Vidal et al.
CANCER RESEARCH (2021)
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells
Yuhang Peng et al.
CELL COMMUNICATION AND SIGNALING (2021)
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities
Ruth Fluemann et al.
BLOOD CANCER DISCOVERY (2021)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data (vol 33, pg 2431, 2017)
Aleksandr Ianevski et al.
BIOINFORMATICS (2020)
Old and New Approaches to Target the Hsp90 Chaperone
Jackee Sanchez et al.
CURRENT CANCER DRUG TARGETS (2020)
Response and Resistance to BCR-ABL1-Targeted Therapies
Theodore P. Braun et al.
CANCER CELL (2020)
Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells
Md Hafiz Uddin et al.
HELIYON (2020)
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Nagavarakishore Pillarsetty et al.
CANCER CELL (2019)
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
Zhaohui Gu et al.
NATURE GENETICS (2019)
Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas
Hui-Min Lei et al.
THERANOSTICS (2019)
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response
Sanil Bhatia et al.
BLOOD (2018)
Lmo2 expression defines tumor cell identity during T-cell leukemogenesis
Idoia Garcia-Ramirez et al.
EMBO JOURNAL (2018)
Heat Shock Causes a Reversible Increase in RNA Polymerase II Occupancy Downstream of mRNA Genes, Consistent with a Global Loss in Transcriptional Termination
Joseph F. Cardiello et al.
MOLECULAR AND CELLULAR BIOLOGY (2018)
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
Anuj Khandelwal et al.
NATURE COMMUNICATIONS (2018)
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells
Julia Drube et al.
Oncotarget (2018)
The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease
Abdullah Hoter et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL
Giacomo Janson et al.
BIOINFORMATICS (2017)
Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression
M. Zou et al.
ONCOGENE (2017)
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
Arefeh Rouhi et al.
ONCOTARGET (2017)
RNA polymerase II pausing and transcriptional regulation of the HSP70 expression
Heeyoun Bunch
EUROPEAN JOURNAL OF CELL BIOLOGY (2017)
Targeting Heat Shock Proteins in Cancer: A Promising Therapeutic Approach
Suman Chatterjee et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
The HSP90 chaperone machinery
Florian H. Schopf et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data
Aleksandr Ianevski et al.
BIOINFORMATICS (2017)
Mechanisms of Hsp90 regulation
Chrisostomos Prodromou
BIOCHEMICAL JOURNAL (2016)
Heat Shock Proteins Promote Cancer: It's a Protection Racket
Stuart K. Calderwood et al.
TRENDS IN BIOCHEMICAL SCIENCES (2016)
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias
Nicole Kucine et al.
BLOOD (2015)
N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes
Y. Wang et al.
CHEMICAL COMMUNICATIONS (2015)
Heat-shock protein 90 inhibitors: will they ever succeed as chemotherapeutics?
Yao Wang et al.
FUTURE MEDICINAL CHEMISTRY (2015)
Maximizing the Therapeutic Potential of HSP90 Inhibitors
Lisa M. Butler et al.
MOLECULAR CANCER RESEARCH (2015)
THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing
Kyle A. Nilson et al.
MOLECULAR CELL (2015)
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Hongliang Zong et al.
CELL REPORTS (2015)
Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions
Komal Jhaveri et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells
Wen-Liang Tian et al.
GENE (2014)
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol
Gunnar Cario et al.
HAEMATOLOGICA (2014)
MDR1 expression predicts outcome of Ph plus chronic phase CML patients on second-line nilotinib therapy after imatinib failure
M. Agrawal et al.
LEUKEMIA (2014)
An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
Huiqiong Lin et al.
EXPERIMENTAL CELL RESEARCH (2013)
A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
Dan Zhou et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells
Monica Pallis et al.
BMC PHARMACOLOGY & TOXICOLOGY (2013)
Chaperoning steroidal physiology: Lessons from mouse genetic models of Hsp90 and its cochaperones
Edwin R. Sanchez
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2012)
Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention
Hakon Reikvam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
The hERG Channel Is Dependent upon the Hsp90α Isoform for Maturation and Trafficking
Laura B. Peterson et al.
MOLECULAR PHARMACEUTICS (2012)
The role of FKBP5 in cancer aetiology and chemoresistance
L. Li et al.
BRITISH JOURNAL OF CANCER (2011)
Heat-shock protein expression in leukemia
Lucie Sedlackova et al.
TUMOR BIOLOGY (2011)
Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits
Dimitris Stellas et al.
BMC CELL BIOLOGY (2010)
Modulation of immune cell signalling by the leukocyte common tyrosine phosphatase, CD45
A. E. Saunders et al.
CELLULAR SIGNALLING (2010)
Targeting HSP90 for cancer therapy
D. Mahalingam et al.
BRITISH JOURNAL OF CANCER (2009)
The regulatory mechanism of Hsp90α secretion and its function in tumor malignancy
Xiaofeng Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A comparison of Hsp90α and Hsp90β interactions with cochaperones and substrates
Aliakbar Taherian et al.
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE (2008)
Interaction of heat-shock protein 90β isoform (HSP90β) with cellular inhibitor of apoptosis 1 (c-IAP1) is required for cell differentiation
C. Didelot et al.
CELL DEATH AND DIFFERENTIATION (2008)
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
Pascale Flandrin et al.
CELL STRESS & CHAPERONES (2008)
A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion
S. Tsutsumi et al.
ONCOGENE (2008)
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Cong Peng et al.
BLOOD (2007)
Multidrug resistance, in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease
Nadja Triller et al.
LUNG CANCER (2006)
Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors
Robert M. Immormino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
Fumitaka Koga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The topoisomerase II-Hsp90 complex: A new chemotherapeutic target?
CR Barker et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage
CR Barker et al.
NUCLEIC ACIDS RESEARCH (2006)
Functional proteomic screens reveal an essential extracellular role for hsp90α in cancer cell invasiveness
BK Eustace et al.
NATURE CELL BIOLOGY (2004)
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
AD Basso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90
ME Gorre et al.
BLOOD (2002)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
